Bioxyne Limited
BXN.ASXConsumer Staples
Biotechnology.
Market Data
$0.080
+0.0%$178.5M
20.0x
$0.004
0.00%
+0.4%
Recent Announcements
Stronger H1 FY2026 Performance Upward Revision to Guidance
Bioxyne delivered a strong H1 FY26 performance with adjusted EBITDA of $8.3M (up from $3.7M pcp), driving an upgraded full-year guidance to $16.5-19.0M (previously $11.5-13.5M). Revenue of $31.3M was well above prior year's $12.6M, with management citing successful margin expansion and efficient business scaling. Key points: Adjusted EBITDA guidance upgraded by 43-41% to $16.5-19.0M from $11.5-13.5M; H1 FY26 adjusted EBITDA of $8.3M representing 124% growth vs pcp; Revenue surged 148% to $31.3M from $12.6M in prior period
Bioxyne Webinar Half Year Results Review 26 Feb 11am AEDT
This is an announcement for an upcoming investor webinar by Bioxyne Limited (ASX: BXN) scheduled for February 26, 2026, to discuss H1 FY26 results. No actual financial results are disclosed in this document as it's merely a webinar invitation. The company operates in pharmaceuticals and psychedelic compounds through its subsidiary Breathe Life Sciences. Key points: Company operates in growing psychedelic therapeutics market through Breathe Life Sciences subsidiary; Multi-national operations across Australia, UK, Europe, Japan with GMP-licensed manufacturing; Market leading manufacturer of therapeutic cannabis, MDMA, and Psilocybin in Australia
Get real-time alerts for BXN
Receive AI-powered earnings summaries and instant notifications when Bioxyne Limited releases results.
Register Free